Medical Pharmacology: Chapter 21: Histamine and Bradykinin Pharmacology -- Module 3: H2 Antagonists, Mast Cell Stabilizers, Anaphylaxis Management, and Bradykinin Physiology

Chapter 21: Histamine and Bradykinin Pharmacology — Module 3: H2 Antagonists, Mast Cell Stabilizers, Anaphylaxis Management, and Bradykinin Physiology

1. A 74-year-old man with chronic atrial fibrillation and a mechanical mitral valve is maintained on warfarin with a target INR of 2.5–3.5. His cardiologist has carefully titrated his dose over six months to achieve stable anticoagulation. He now presents to his primary care physician with epigastric pain and is found to have a non-bleeding duodenal ulcer on endoscopy. His primary care physician prescribes cimetidine 400 mg twice daily without consulting the patient's medication list. Four weeks later the patient returns with gingival bleeding and bruising; his INR is 5.6. Which of the following most accurately identifies the prescribing error and the pharmacological principle that should have guided drug selection?

A) The prescribing error was failing to reduce the warfarin dose prophylactically when starting any H2 receptor antagonist, since all agents in this class inhibit vitamin K-dependent clotting factor synthesis through a shared mechanism of CYP2C9 inhibition; the correct approach is to reduce warfarin by 30% whenever any H2RA is initiated
B) The prescribing error was choosing cimetidine over a proton pump inhibitor; PPIs have no CYP inhibitory activity and would have provided superior acid suppression without the drug interaction; H2RAs as a class are contraindicated in patients receiving warfarin because their gastric acid suppression alters warfarin absorption from the proximal duodenum
C) The prescribing error was not checking the INR weekly during the first month of any new medication, since pharmacokinetic interactions with warfarin are unpredictable; the specific drug chosen is irrelevant because all acid-suppressing agents interact with warfarin through competitive displacement from plasma protein binding sites
D) The prescribing error was selecting cimetidine — which inhibits CYP2C9 through its imidazole ring's coordination with the CYP heme iron, reducing clearance of the pharmacologically active S-warfarin enantiomer and causing drug accumulation at an unchanged dose — in a patient on warfarin; famotidine or nizatidine, which lack the imidazole ring and do not inhibit CYP2C9, should have been selected, or a PPI could have been used as an alternative without this interaction
E) The prescribing error was prescribing an H2 receptor antagonist rather than sucralfate for a patient on anticoagulation; sucralfate forms a protective mucosal barrier without systemic absorption and therefore has no drug interactions, making it the preferred agent for peptic ulcer disease in all anticoagulated patients regardless of ulcer severity or healing requirements

ANSWER: D

Rationale:

This question asked you to identify a prescribing error rooted in a well-characterized drug interaction and name the pharmacological principle that should have guided agent selection. Cimetidine inhibits multiple CYP isoforms — CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 — through its imidazole ring nitrogen's coordination with the heme iron of cytochrome P450 enzymes. CYP2C9 is the primary enzyme responsible for oxidative metabolism of S-warfarin, the more potent enantiomer. When cimetidine inhibits CYP2C9, S-warfarin clearance falls, steady-state plasma concentrations rise at the same daily dose, and the anticoagulant effect intensifies — producing the supratherapeutic INR and bleeding observed here. Famotidine and nizatidine lack the imidazole ring and do not inhibit CYP2C9 or any other CYP isoform at therapeutic doses, making either a safe H2RA choice in this patient. A proton pump inhibitor (PPI) would also have been acceptable — PPIs are metabolized by CYP2C19 (omeprazole, esomeprazole) or CYP3A4 (pantoprazole), and while some PPIs have weak CYP2C19 inhibitory activity, clinically significant warfarin interactions with PPIs are uncommon and do not approach the magnitude of the cimetidine-warfarin interaction.

Option A: Option A is incorrect because not all H2RAs inhibit CYP2C9 — only cimetidine does, through its imidazole ring; famotidine and nizatidine have no clinically meaningful CYP inhibitory activity and do not require prophylactic warfarin dose reduction; a class-wide contraindication and mandatory 30% dose reduction is pharmacologically unjustified.
Option B: Option B is incorrect in its mechanism — H2RAs do not interact with warfarin through altered absorption from the duodenum; the interaction is pharmacokinetic (reduced hepatic CYP2C9-mediated warfarin metabolism), not absorptive; while PPIs are a reasonable alternative, labeling all H2RAs as contraindicated in warfarin-treated patients is incorrect because famotidine and nizatidine are safe.
Option C: Option C is incorrect because the drug-specific interaction with warfarin is entirely predictable from cimetidine's known CYP2C9 inhibitory activity — this is not an unpredictable pharmacokinetic interaction; regular INR monitoring is always appropriate in anticoagulated patients but does not substitute for selecting the correct drug in the first place; protein displacement is not the mechanism.
Option E: Option E is incorrect because sucralfate is not the universally preferred agent for peptic ulcer disease in anticoagulated patients — duodenal ulcers require healing with acid suppression, and sucralfate alone is generally inferior to H2RAs or PPIs for ulcer healing; moreover, the claim that sucralfate has no drug interactions is inaccurate — it can reduce absorption of several drugs including fluoroquinolones, tetracycline, and warfarin itself if given concomitantly.

2. An 82-year-old woman with moderate chronic kidney disease (eGFR 28 mL/min) and a history of peptic ulcer disease is admitted from a nursing home with acute confusion, agitation, and visual hallucinations that began two days ago. She has no fever, normal white cell count, negative urinalysis, and no focal neurological deficits. Review of her medication administration record reveals she was started on famotidine 40 mg twice daily three weeks ago for recurrent heartburn, without renal dose adjustment. Her baseline cognitive function was intact. Which of the following is the most likely explanation for her presentation and the correct immediate management?

A) Famotidine has accumulated to toxic plasma concentrations due to her reduced GFR — the drug is predominantly renally eliminated as unchanged drug, and at eGFR 28 mL/min its clearance is markedly reduced; all H2 receptor antagonists cross the blood-brain barrier and produce CNS toxicity at supratherapeutic concentrations; the correct management is to discontinue famotidine and provide supportive care, with expectation that symptoms will resolve as drug is cleared
B) Famotidine caused a paradoxical central histamine excess by blocking peripheral H2 receptors and driving compensatory upregulation of central H2 receptors in the hippocampus; the increased central H2 receptor density amplifies histamine neurotransmission, producing a hyperexcitable state manifesting as agitation and hallucinations; the correct management is to add an H1 antihistamine to suppress the central histamine excess while continuing famotidine for acid control
C) The confusion represents cimetidine-type anticholinergic toxicity — famotidine, like cimetidine, has significant muscarinic receptor blocking activity that becomes clinically apparent in elderly patients with reduced drug clearance; the syndrome is characterized by confusion, agitation, hallucinations, dry mouth, urinary retention, and tachycardia; the correct management is physostigmine 1–2 mg IV to reverse the central and peripheral anticholinergic effects
D) Famotidine precipitated acute uremic encephalopathy by inhibiting renal tubular secretion of urea through an OCT2 transporter blocking mechanism; the resulting BUN elevation crossed a critical threshold in this patient with underlying CKD, producing the encephalopathy observed; the correct management is hemodialysis to clear the urea burden while discontinuing famotidine
E) The patient developed famotidine-induced serotonin syndrome through inhibition of CYP2D6-mediated serotonin metabolism; at reduced clearance in renal impairment, famotidine achieves plasma concentrations sufficient to inhibit CYP2D6 in the CNS, impairing serotonin breakdown and producing the agitation and visual hallucinations observed; the correct management is cyproheptadine to block central serotonin receptors

ANSWER: A

Rationale:

This question asked you to apply knowledge of famotidine's renal elimination and CNS adverse effect potential to a classic clinical scenario — an elderly nursing home patient who develops delirium after starting an H2RA at a standard dose not adjusted for renal function. Famotidine is predominantly renally eliminated: approximately 65–70% of the administered dose is excreted unchanged in the urine, and its clearance falls proportionally with GFR. At eGFR 28 mL/min, famotidine's half-life is substantially extended compared to normal renal function, and standard twice-daily dosing produces progressive drug accumulation to plasma concentrations well above the therapeutic range. All H2 receptor antagonists cross the blood-brain barrier to varying degrees — famotidine, cimetidine, and ranitidine have all been implicated in CNS toxicity including confusion, agitation, delirium, and hallucinations at elevated plasma concentrations. Cimetidine is most commonly cited because it accumulates most readily in renally impaired patients and has additional CNS effects, but famotidine is not exempt from this adverse effect class, particularly at accumulating concentrations in elderly patients with CKD. The presentation — subacute onset of confusion, agitation, and hallucinations in a cognitively intact elderly patient two to three weeks after starting an H2RA without renal dose adjustment — is a textbook presentation of H2RA neurotoxicity. Management is discontinuation of the offending drug, supportive care, and monitoring for resolution as the drug is cleared.

Option B: Option B is incorrect because compensatory central H2 receptor upregulation producing a hyperexcitable encephalopathy is not an established mechanism of H2RA toxicity — the CNS adverse effects of H2RAs are not mediated through receptor upregulation driving excess histamine neurotransmission; adding an H1 antihistamine to a patient with drug accumulation would provide no benefit and the mechanism described is pharmacologically fabricated.
Option C: Option C is incorrect because famotidine does not have clinically significant muscarinic receptor blocking activity — it is an H2 receptor antagonist without anticholinergic pharmacology; the anticholinergic toxidrome (dry mouth, urinary retention, tachycardia, flushed skin) is not caused by famotidine; attributing anticholinergic syndrome to famotidine conflates this drug with atropine-class agents.
Option D: Option D is incorrect because famotidine does not inhibit OCT2-mediated urea secretion and does not cause uremic encephalopathy through urea retention — urea is freely filtered and not actively secreted by OCT2; the pharmacological mechanism described is fabricated, and uremic encephalopathy from BUN elevation caused by famotidine has no pharmacological basis.
Option E: Option E is incorrect because famotidine is not a CYP2D6 inhibitor — it lacks the imidazole ring that confers CYP inhibitory activity to cimetidine; famotidine does not inhibit serotonin metabolism through CYP2D6, and serotonin syndrome from famotidine is not an established clinical entity.

3. A 19-year-old college student with allergic asthma uses inhaled cromolyn sodium as prescribed by her allergist for prevention of exercise-induced bronchospasm. She arrives at the student health center in moderate respiratory distress after a cat exposure at a friend's apartment. She is wheezing with a respiratory rate of 26 and peak flow 52% of predicted. She states she inhaled her cromolyn immediately upon noticing symptoms. She does not have her albuterol inhaler with her. The nurse notes the cromolyn was used correctly and suggests it should take effect shortly. Which of the following correctly evaluates the nurse's expectation and identifies the appropriate action?

A) The nurse's expectation is correct — cromolyn takes approximately 20–30 minutes to reach its peak effect because it must accumulate in the airway mucosa before blocking calcium channels on mast cell surfaces; the student should be reassured and monitored for 30 minutes before additional intervention is considered
B) The nurse's expectation is correct for a patient who has been using cromolyn regularly, since chronic use builds a protective mast cell stabilizing effect that reduces the intensity of acute reactions; a single acute dose will not fully abort the attack but will reduce its severity over the next 15 minutes, and nebulized saline can be administered while waiting for the cromolyn to take effect
C) The nurse's expectation is incorrect — cromolyn stabilizes mast cells against degranulation before allergen exposure and has no therapeutic effect once degranulation has already occurred; in this patient, mast cells began releasing histamine, leukotrienes, and other mediators the moment she was exposed to cat allergen; inhaling cromolyn after symptoms begin cannot reverse mediator release already in progress; a short-acting beta-2 agonist such as albuterol is the correct rescue agent and should be obtained immediately
D) The nurse's expectation is correct for cat allergen specifically because cat dander allergen (Fel d 1) binds to IgE with particularly slow kinetics, and cromolyn taken within 10 minutes of exposure can still competitively displace Fel d 1 from mast cell-bound IgE before full receptor cross-linking occurs; for this allergen type, post-exposure cromolyn is pharmacologically effective if given within the first 15 minutes of symptoms
E) The nurse's expectation is incorrect, but for a different reason — inhaled cromolyn does not stabilize mast cells in the lower airways because its molecular weight prevents it from reaching the alveolar level; it acts only in the upper airway and nasal mucosa; the wheezing reflects lower airway bronchoconstriction driven by mediators from sub-segmental mast cells that cromolyn cannot reach; oral cromolyn would be required to address lower airway mast cell activation

ANSWER: C

Rationale:

This question asked you to apply cromolyn's mechanism and its strict timing requirement to a clinical scenario where the drug is being used incorrectly — after rather than before allergen exposure — and to recognize the clinical consequence and correct response. Cromolyn sodium stabilizes mast cells by interfering with calcium ion flux required for granule-plasma membrane fusion during exocytosis. This mechanism is entirely preventive: it prevents degranulation from occurring when a mast cell is subsequently activated. Once allergen has cross-linked surface IgE and the degranulation cascade has been triggered — which occurs within seconds to minutes of allergen exposure — the calcium flux has already happened and granules are already fusing with the plasma membrane. At this point, cromolyn has nothing to stabilize because the event it prevents has already occurred. The clinical corollary is absolute: cromolyn cannot abort, shorten, or reduce the severity of an allergic reaction already underway. This patient's wheezing represents bronchospasm driven by histamine, cysteinyl leukotrienes, and prostaglandin D2 already released from mast cells in her airways. The cromolyn she inhaled will have no effect on these released mediators or on the smooth muscle contraction they have already initiated. The correct rescue agent is a short-acting beta-2 agonist — albuterol/salbutamol by MDI or nebulizer — which directly reverses bronchospasm through beta-2 receptor-mediated smooth muscle relaxation.

Option A: Option A is incorrect because the 20–30 minute timeline described as "time to peak effect" does not apply to a rescue scenario — cromolyn has no rescue effect regardless of how long one waits after allergen exposure; the drug's mechanism is prophylactic, not therapeutic, and waiting while the patient has a 52% peak flow and moderate respiratory distress risks clinical deterioration.
Option B: Option B is incorrect because regular prophylactic use of cromolyn does not confer any enhanced acute rescue effect — cumulative mast cell stabilization does not reduce the severity of an attack already in progress; nebulized saline has no bronchodilator effect and would not be an appropriate substitute for a rescue bronchodilator in a patient with moderate bronchospasm.
Option D: Option D is incorrect because cromolyn does not compete with allergen for IgE binding and has no ability to displace allergen from IgE regardless of its kinetics; cromolyn acts intracellularly on the calcium flux pathway in mast cells, not at the IgE-allergen binding interface; there is no allergen-specific window during which post-exposure cromolyn is pharmacologically effective.
Option E: Option E is incorrect because inhaled cromolyn does penetrate the lower airways when delivered correctly by MDI or nebulizer — it reaches bronchial and bronchiolar mast cells; the mechanistic problem is not anatomical penetration but temporal: the drug cannot reverse completed degranulation; claiming it acts only in the upper airway is pharmacologically incorrect.

4. A 38-year-old woman with severe allergic asthma has been receiving omalizumab injections at her allergist's office every four weeks for the past six months. Today she received her scheduled injection, was observed for 30 minutes without incident, and was discharged home. Approximately four hours later she calls the office describing generalized urticaria, throat tightness, and dizziness. She has an epinephrine auto-injector at home prescribed at her last visit but has not used it because she believes her reaction is too mild and she should first try oral diphenhydramine. Which of the following best identifies the nature of her reaction and provides the correct guidance?

A) This is a delayed allergic reaction to the omalizumab excipients rather than to the antibody itself — delayed reactions to polysorbate or sucrose in biologic formulations are IgG-mediated and typically milder than IgE-mediated anaphylaxis; oral diphenhydramine is appropriate initial management for this class of reaction and epinephrine should be reserved for reactions with hypotension or loss of consciousness
B) This is a biphasic reaction to a prior allergen exposure rather than an omalizumab adverse effect — the 30-minute observation period was sufficient to exclude omalizumab as the cause; she should take oral diphenhydramine and present to the emergency department only if symptoms progress to involve respiratory compromise
C) This presentation is consistent with a serum sickness-like reaction to omalizumab occurring at the expected 4–7 day timeframe; the correct management is oral corticosteroids for 5–7 days to suppress the immune complex-mediated inflammation; epinephrine is not indicated for type III hypersensitivity reactions
D) The reaction represents an expected pharmacodynamic effect of IgE depletion — as circulating IgE falls rapidly after injection, mast cells upregulate Fc-epsilon-RI receptors to compensate, transiently increasing their sensitivity to any circulating allergen; this self-limited hypersensitivity surge resolves within 12–24 hours; the patient should take diphenhydramine and avoid allergen triggers for 24 hours
E) This is likely a delayed anaphylactic reaction to omalizumab — a well-recognized pattern in which reactions occur hours after injection and after the standard 30-minute observation window; throat tightness and dizziness in this context represent potential airway and hemodynamic compromise; she should immediately administer her epinephrine auto-injector into the thigh, call emergency services, and go to the nearest emergency department regardless of apparent symptom severity

ANSWER: E

Rationale:

This question asked you to apply knowledge of omalizumab's distinctive delayed anaphylaxis risk profile — and the clinical management of anaphylaxis — to a patient making a dangerous self-management decision at home. Anaphylaxis from omalizumab occurs in approximately 0.1% of patients and has a characteristic temporal pattern: while some reactions occur within 30–60 minutes of injection (within the standard observation window), a clinically significant proportion occur hours after injection — a pattern unique to omalizumab among subcutaneous biologics and the reason patients are specifically educated to use an epinephrine auto-injector at home. This patient's presentation — generalized urticaria plus throat tightness plus dizziness occurring four hours after omalizumab injection — represents a multisystem allergic reaction with airway and hemodynamic involvement, meeting clinical criteria for anaphylaxis. Throat tightness indicates pharyngeal or laryngeal involvement, and dizziness suggests cardiovascular compromise; these are not mild manifestations. The correct management is immediate epinephrine administration (IM into the vastus lateralis), activation of emergency services (911), and emergency department evaluation. Waiting to try oral diphenhydramine — which has a slow onset, addresses only H1-mediated components, and has no effect on airway swelling or hemodynamic compromise — risks allowing the anaphylaxis to progress to laryngeal obstruction or cardiovascular collapse during the delay.

Option A: Option A is incorrect because reaction severity, not the specific triggering molecule, determines whether epinephrine is indicated; throat tightness and dizziness require epinephrine regardless of the excipient hypothesis; IgG-mediated reactions to excipients do not produce the multisystem presentation described, and withholding epinephrine until hypotension or loss of consciousness develops is dangerous — epinephrine should be given at the first signs of anaphylaxis.
Option B: Option B is incorrect because the 30-minute observation period does not exclude omalizumab as the cause — delayed anaphylaxis beyond the observation window is a documented and specifically warned adverse effect of omalizumab; attributing this reaction to a prior allergen exposure without any such exposure mentioned is speculative reasoning that would delay life-saving treatment.
Option C: Option C is incorrect because serum sickness occurs 7–14 days after drug exposure, not 4 hours; the presentation described — urticaria, throat tightness, and dizziness within hours of injection — is not consistent with serum sickness (which presents with fever, arthralgias, lymphadenopathy, and urticaria over days); corticosteroids are not the first-line treatment for acute anaphylaxis.
Option D: Option D is incorrect because transient mast cell hypersensitivity from Fc-epsilon-RI upregulation is not an established pharmacodynamic explanation for post-omalizumab reactions; this mechanism is pharmacologically fabricated; the patient's symptoms of throat tightness and dizziness are not self-limited hypersensitivity surges that resolve safely with diphenhydramine.

5. A 22-year-old man with a known shellfish allergy arrives in the emergency department 10 minutes after ingesting shrimp at a restaurant. He has generalized urticaria, mild wheezing, BP 98/62, and HR 118. An intern assesses the patient and administers epinephrine 0.3 mg subcutaneously into the anterior abdominal wall, then reassesses five minutes later and notes minimal improvement. The attending reviews the case and immediately corrects the management. Which of the following correctly identifies the error and explains the pharmacological basis for the attending's concern?

A) The error was administering 0.3 mg rather than the correct adult dose of 0.5 mg; subcutaneous injection is acceptable and achieves comparable peak plasma concentrations to intramuscular injection in the thigh, but the dose was insufficient to produce meaningful alpha-1 vasoconstriction and beta-2 bronchodilation at the receptor level given the degree of mediator release in this patient
B) The error was the route and site of administration — subcutaneous injection produces slower and less reliable peak plasma epinephrine concentrations than intramuscular injection into the vastus lateralis, partly because epinephrine causes local alpha-1-mediated vasoconstriction at the subcutaneous injection site, which slows its own absorption; the correct administration is 0.3 mg intramuscularly into the mid-outer thigh, which has higher vascularity and produces faster, more reliable systemic concentrations
C) The error was administering epinephrine before antihistamines — diphenhydramine and famotidine should be given first to block H1 and H2 receptors and reduce ongoing histamine release, and epinephrine should be reserved for patients who do not respond to combined antihistamine therapy within 15 minutes; premature epinephrine use risks hypertensive crisis in young patients with strong adrenergic responses
D) The error was using standard epinephrine 1:1000 solution subcutaneously; the subcutaneous route requires the more dilute 1:10,000 concentration to prevent tissue ischemia from local vasoconstriction; the 1:1000 concentration is appropriate for intramuscular injection only; the patient should receive 3 mL of the 1:10,000 solution subcutaneously to deliver the correct 0.3 mg dose at the appropriate dilution
E) The error was failing to give epinephrine intravenously — subcutaneous and intramuscular injections are both inferior to intravenous administration for anaphylaxis because only IV delivery guarantees immediate systemic distribution; in any patient with hypotension from anaphylaxis, IV epinephrine at the 1:10,000 concentration should be the initial route regardless of whether IV access was established before or after the first dose

ANSWER: B

Rationale:

This question asked you to identify a specific route-of-administration error in anaphylaxis management and explain the pharmacological mechanism that makes the chosen route suboptimal. In anaphylaxis, the speed of achieving effective plasma epinephrine concentrations is critical — delays allow ongoing mediator release, worsening vasodilation, bronchospasm, and airway edema. Subcutaneous (SC) injection is pharmacologically inferior to intramuscular (IM) injection in the vastus lateralis for two reasons: first, subcutaneous tissue has lower vascularity than muscle, so absorption is slower; second, epinephrine itself causes alpha-1 adrenergic receptor-mediated vasoconstriction at the injection site, which actively slows its own systemic absorption when injected subcutaneously — a pharmacological paradox that does not apply to IM injection because muscle vascularity is less susceptible to this local vasoconstrictive effect. Studies measuring plasma epinephrine concentrations after SC versus IM injection demonstrate that IM injection into the vastus lateralis achieves faster and higher peak concentrations than SC injection. The anterior abdominal wall compounds this problem with variable subcutaneous fat thickness. The correct administration in anaphylaxis is 0.3–0.5 mg (0.3–0.5 mL of 1:1000 solution) IM into the mid-outer thigh (vastus lateralis). The 0.3 mg dose itself is within the correct range for an adult, so the dose was not the error.

Option A: Option A is incorrect because subcutaneous injection does not achieve comparable peak concentrations to IM injection — the pharmacokinetic data clearly show IM vastus lateralis injection is superior; dose insufficiency is not the primary error, as 0.3 mg is within the accepted adult range.
Option C: Option C is incorrect because epinephrine is the first-line treatment for anaphylaxis and should never be withheld pending antihistamine therapy — antihistamines are adjuncts that address only the histamine-mediated components of anaphylaxis and cannot reverse the multimediator hemodynamic and airway compromise; withholding epinephrine in a patient with hypotension while waiting to assess antihistamine response is clinically dangerous and contradicts all major guidelines.
Option D: Option D is incorrect because the 1:1000 concentration of epinephrine is the standard formulation for IM injection in anaphylaxis — it does not cause dangerous tissue ischemia when given IM; the 1:10,000 concentration is reserved for IV administration (where the more dilute concentration reduces the risk of hypertensive crisis from rapid vascular delivery); using a 3 mL volume of 1:10,000 subcutaneously to deliver 0.3 mg would be pharmacologically equivalent in dose but would not correct the route-of-administration error.
Option E: Option E is incorrect because intravenous epinephrine is not the standard first-line route in anaphylaxis — it is reserved for patients with cardiovascular collapse refractory to repeated IM doses; IV bolus of epinephrine carries significant risk of hypertensive crisis and fatal arrhythmia if given at the wrong concentration or rate, and recommending IV epinephrine as the initial route in all hypotensive anaphylaxis patients overstates its role and introduces unnecessary risk.

6. A 64-year-old man with hypertension treated with propranolol 80 mg twice daily is brought to the emergency department after developing anaphylaxis during a penicillin infusion. He is profoundly hypotensive (BP 68/40), bradycardic (HR 38), and has audible wheezing. He has received two intramuscular doses of epinephrine 0.3 mg into the vastus lateralis five minutes apart with no improvement in blood pressure or heart rate. Which of the following correctly identifies why epinephrine has failed to produce its expected hemodynamic response and identifies the next appropriate pharmacological intervention?

A) Epinephrine failed because propranolol competitively inhibits alpha-1 adrenergic receptors in addition to beta receptors; the correct intervention is phenylephrine, a pure alpha-1 agonist whose receptor binding is not affected by beta-blocker co-administration, to restore vascular tone without requiring any adrenergic receptor pathway shared with propranolol
B) Epinephrine failed because penicillin anaphylaxis specifically activates complement-mediated bradykinin release that antagonizes epinephrine at the vascular level; the correct intervention is icatibant 30 mg subcutaneously to block bradykinin B2 receptors and restore epinephrine responsiveness by removing the opposing vasodilatory signal
C) Epinephrine failed because propranolol blocks all adrenergic receptors including alpha-1; with alpha-1 vasoconstriction also eliminated, epinephrine has no remaining hemodynamic mechanism available; the correct intervention is high-dose dopamine infusion at 20 mcg/kg/min to activate dopaminergic receptors in the vasculature that are unaffected by propranolol's adrenergic blockade, restoring perfusion pressure through a receptor pathway propranolol does not occupy
D) Epinephrine failed because propranolol occupies beta-1 and beta-2 adrenergic receptors, preventing epinephrine from increasing heart rate or cardiac output and preventing bronchodilation, while alpha-1-mediated vasoconstriction remains active but insufficient alone to restore perfusion; the correct next intervention is glucagon, which activates adenylyl cyclase through its own Gs-coupled glucagon receptor independently of beta-adrenergic receptor occupancy, restoring positive inotropy and chronotropy despite complete beta-blockade
E) Epinephrine failed because the dose of 0.3 mg is the pediatric dose; for an adult male with complete beta-blocker coverage, the required epinephrine dose is 1.0 mg IM, which achieves plasma concentrations sufficient to overcome propranolol's competitive beta-receptor blockade through mass action; the correct intervention is a third dose of epinephrine at 1.0 mg before considering adjunctive agents

ANSWER: D

Rationale:

This question asked you to apply knowledge of propranolol's receptor pharmacology to explain why standard epinephrine dosing fails in anaphylaxis, and to identify the correct pharmacological rescue. Propranolol is a non-selective beta-adrenergic receptor antagonist — it blocks both beta-1 receptors (cardiac: positive inotropy, positive chronotropy) and beta-2 receptors (bronchial smooth muscle: bronchodilation; mast cells: mediator release inhibition). When epinephrine is administered in this setting, its alpha-1 effects (vasoconstriction) remain pharmacologically intact because propranolol does not block alpha receptors. However, epinephrine's beta-1 effects — which would normally increase cardiac output through increased heart rate and contractility — are blocked, and its beta-2-mediated bronchodilation is blocked. The result is the clinical picture seen: persistent bradycardia, poor cardiac output, and refractory bronchospasm despite epinephrine. Glucagon is the pharmacological solution because it activates its own dedicated Gs-coupled glucagon receptor — a receptor structurally distinct from the beta-adrenergic receptor and not occupied by propranolol. Glucagon receptor activation raises cAMP in cardiac myocytes and bronchial smooth muscle through adenylyl cyclase, restoring positive inotropy and chronotropy independent of beta-receptor occupancy. The dose is 1–5 mg IV bolus, followed by infusion at 5–15 micrograms/min. Nausea and vomiting are common adverse effects requiring aspiration precautions.

Option C: Option C is incorrect because propranolol blocks beta-1 and beta-2 receptors but not alpha-1 receptors — alpha-1-mediated vasoconstriction from epinephrine remains active; dopamine at high doses does activate alpha-1 receptors but it also requires intact adrenergic receptor function for its vasopressor effect at lower doses; more importantly, glucagon is the pharmacologically targeted and guideline-recommended intervention for beta-blocker-refractory anaphylaxis, not dopamine infusion, because glucagon acts through a receptor pathway completely independent of propranolol's blockade.
Option A: Option A is incorrect because propranolol does not inhibit alpha-1 adrenergic receptors — it is a beta-selective blocker; phenylephrine would provide additional alpha-1 vasoconstriction but would not address the bradycardia, reduced cardiac output, or bronchospasm that result from beta-receptor blockade; phenylephrine alone cannot restore the hemodynamic response that beta-1 receptor activation by epinephrine normally provides.
Option B: Option B is incorrect because penicillin anaphylaxis is IgE-mediated, not bradykinin-mediated through complement activation — the dominant mediators are histamine, leukotrienes, and PAF from mast cell degranulation; icatibant is indicated for bradykinin-mediated angioedema (HAE or ACEI-induced), not for IgE-mediated anaphylaxis; it would not restore epinephrine responsiveness in this patient.
Option E: Option E is incorrect because epinephrine's failure in beta-blocker-treated patients is not a dose-dependency problem — competitive antagonism by propranolol cannot be overcome by mass action at the doses used clinically without producing severe alpha-1-mediated hypertension; the mechanism of failure is receptor blockade, and the solution is to bypass the blocked receptor through a different pathway (glucagon), not to escalate epinephrine to supratherapeutic doses.

7. A 52-year-old woman of Korean ancestry with hypertension, stage 3 chronic kidney disease, and diabetes with proteinuria has been on lisinopril 20 mg daily for the past four months for blood pressure control and renoprotection. She presents reporting a persistent dry, nonproductive cough that began six weeks after starting the drug. She has tried cough drops and over-the-counter dextromethorphan without relief. Chest radiograph is normal and she is afebrile. Her renal function is stable. Which of the following is the correct management and its pharmacological rationale?

A) Switch to an ARB such as losartan or valsartan — lisinopril inhibits ACE (kininase II), which normally degrades bradykinin and substance P in the bronchial mucosa; bradykinin accumulation sensitizes bronchial C-fibers via B2 receptors and substance P amplifies this through neurokinin-1 receptors, producing the dry cough; ARBs block the AT1 angiotensin receptor downstream of ACE without inhibiting ACE activity, so bradykinin and substance P continue to be degraded normally and cough does not occur; ARBs provide equivalent renoprotection in diabetic nephropathy
B) Continue lisinopril and add inhaled cromolyn sodium — the cough reflects mast cell activation in the bronchial mucosa from bradykinin-driven IgE cross-linking on mast cell surfaces; prophylactic cromolyn will prevent mast cell degranulation and terminate the cough-producing mediator cascade; this approach preserves lisinopril's renoprotective benefit without requiring a drug change
C) Switch to a calcium channel blocker such as amlodipine — the cough is caused by ACE inhibitor-mediated prostaglandin accumulation (not bradykinin), and CCBs directly inhibit prostaglandin synthesis in bronchial epithelial cells at therapeutic plasma concentrations; this would eliminate the cough mechanism while providing blood pressure control, though an alternative agent should be added for proteinuria
D) Continue lisinopril and prescribe codeine 15 mg as needed for cough suppression — ACE inhibitor cough is a known pharmacological effect that is dose-independent and resolves over 6–12 months in most patients as bradykinin receptor desensitization develops; opioid antitussives effectively suppress the cough reflex during this adaptation period without requiring a medication change that would disrupt stable renal protection
E) Switch to a thiazide diuretic such as hydrochlorothiazide — the cough reflects ACE inhibitor-induced bronchial edema from bradykinin-mediated vascular permeability, and thiazide diuretics reduce bronchial edema through their natriuretic effect; hydrochlorothiazide also provides adequate blood pressure control and reduces proteinuria through reduction in glomerular capillary pressure in CKD

ANSWER: A

Rationale:

This question asked you to apply knowledge of ACE inhibitor-induced cough — mechanism, risk factors, and correct management — to a patient in whom the diagnosis is straightforward but the correct substitute drug must also preserve the clinical indication. The mechanism: lisinopril inhibits ACE (kininase II), which normally degrades bradykinin and substance P to inactive fragments in the pulmonary and bronchial mucosa. Bradykinin accumulates and activates B2 receptors on bronchial sensory C-fibers, generating prostaglandins and activating TRPV1 ion channels, sensitizing the cough reflex. Substance P, also an ACE substrate, amplifies this through neurokinin-1 receptors on the same fibers. The resulting dry, nonproductive cough does not respond to antitussives, antihistamines, or corticosteroids because the trigger is not histamine or a suppressible reflex — it is bradykinin-driven C-fiber sensitization. This patient's Korean ancestry is relevant: East Asian patients have up to 30–40% incidence of ACE inhibitor cough compared to 5–15% in European ancestry patients. The correct management is switching to an ARB, which blocks the AT1 angiotensin receptor downstream of ACE without inhibiting ACE enzymatic activity — bradykinin and substance P degradation continues normally, cough resolves within days to weeks of stopping the ACE inhibitor, and ARBs provide equivalent renoprotective benefit in diabetic nephropathy with proteinuria.

Option B: Option B is incorrect because ACE inhibitor cough is not mediated by IgE-dependent mast cell degranulation — bradykinin does not cross-link IgE on mast cells; cromolyn stabilizes mast cells against allergen-triggered degranulation, a mechanism entirely unrelated to bradykinin-driven C-fiber sensitization; cromolyn would have no effect on this cough.
Option C: Option C is incorrect because ACE inhibitor cough is bradykinin-mediated (not prostaglandin-mediated), and calcium channel blockers do not inhibit prostaglandin synthesis in bronchial epithelium; the proposed mechanism is pharmacologically incorrect; amlodipine does not address the renoprotective indication in diabetic proteinuric CKD as effectively as RAAS blockade.
Option D: Option D is incorrect because ACE inhibitor cough does not resolve spontaneously over 6–12 months in most patients — it persists as long as the drug is continued and resolves only after discontinuation; bradykinin receptor desensitization does not overcome the sustained cough-producing mechanism; opioid antitussives while continuing the causative drug is inappropriate management when a safe and effective alternative (ARB) exists.
Option E: Option E is incorrect because the mechanism of ACE inhibitor cough is not bronchial edema from vascular permeability — it is C-fiber sensitization; thiazide diuretics have no effect on bradykinin-mediated C-fiber sensitization; hydrochlorothiazide does not provide the same degree of proteinuria reduction and renoprotection as RAAS blockade in diabetic nephropathy.

8. A 58-year-old African American man on ramipril for hypertension and heart failure presents to the emergency department with rapidly progressive tongue and oropharyngeal swelling that began one hour ago. There is no urticaria, no pruritus, and no identifiable food or drug trigger other than his chronic medications. SpO2 is 93% on room air and stridor is audible. The treating resident diagnoses allergic angioedema and administers diphenhydramine 50 mg IV, methylprednisolone 125 mg IV, and subcutaneous epinephrine 0.3 mg. Forty-five minutes later, swelling is unchanged and the patient is becoming more anxious with worsening stridor. The attending arrives and immediately identifies a critical error. Which of the following reflects the attending's assessment?

A) The error was administering epinephrine subcutaneously rather than intramuscularly — if the epinephrine had been given intramuscularly into the vastus lateralis at the outset, it would have achieved peak plasma concentrations sufficient to reverse the bradykinin-mediated permeability increase; a repeat dose of 0.5 mg IM should be given immediately and the patient monitored for response before airway intervention is considered
B) The error was the diagnosis — this presentation is hereditary angioedema type I masquerading as ACEI angioedema; the absence of urticaria and failure to respond to standard anaphylaxis therapy confirm HAE; C1 inhibitor antigen levels should be drawn immediately and icatibant administered while waiting for results; ramipril should be continued because it is unrelated to the HAE attack
C) The error was diagnosing this as allergic angioedema when the clinical picture is consistent with ACE inhibitor-induced bradykinin-mediated angioedema — the absence of urticaria, the patient's ramipril use, and African American race (threefold to fivefold higher risk) are all characteristic features; bradykinin-mediated angioedema does not respond reliably to epinephrine, antihistamines, or corticosteroids because histamine is not the mediator; the priority is securing the airway now, ramipril must be permanently discontinued, and bradykinin-targeted therapy should be considered
D) The error was not escalating to IV epinephrine — subcutaneous epinephrine provides less than 40% systemic bioavailability compared to IV administration; in a patient with progressive airway compromise, only IV epinephrine at the 1:10,000 concentration can achieve the plasma concentrations required to reverse bradykinin-mediated endothelial permeability; 1 mg IV epinephrine should be administered immediately
E) The error was omitting H2 blockade — the combined H1 plus H2 antihistamine strategy is required for all angioedema presentations because H2 receptors on submucosal vasculature mediate bradykinin-stimulated permeability increase in the oropharynx; adding famotidine 20 mg IV would block the H2-mediated component of the swelling and should produce clinical improvement within 15–20 minutes

ANSWER: C

Rationale:

This question asked you to identify a diagnostic error in real time and explain its pharmacological consequence — recognizing that a patient receiving ineffective treatment for a progressive airway emergency requires both correct diagnosis and correct management without delay. The clinical features are characteristic of ACE inhibitor-induced bradykinin-mediated angioedema: progressive oropharyngeal swelling without urticaria (histamine-mediated angioedema is almost always accompanied by urticaria), no identifiable allergen other than ramipril, African American ancestry (three- to fivefold higher risk than White patients), and complete failure to respond to epinephrine, antihistamines, and corticosteroids over 45 minutes. The pharmacological basis for treatment failure is mechanistic: ACEI angioedema is driven by bradykinin accumulation at the dermal and submucosal vasculature, where bradykinin activates B2 receptors and generates nitric oxide and prostacyclin through Gq-PLC-calcium-eNOS and PLA2-COX-1 pathways. These permeability-increasing mediators are not histamine, and antihistamines targeting H1 receptors have no effect on NO- and prostacyclin-driven endothelial gap formation. Epinephrine's alpha-1 vasoconstriction can partially counteract some vasodilation but cannot reliably reverse the bradykinin-driven permeability as it does in histamine-mediated reactions. The immediate clinical priority is airway — the patient has SpO2 93%, audible stridor, and progressive swelling; early definitive airway management (intubation or surgical airway) is required before the tongue enlarges further and obstructs the view. Ramipril must be permanently discontinued and rechallenge is absolutely contraindicated.

Option A: Option A is incorrect because the route of epinephrine administration is not the primary error — the primary error is the diagnosis; even IM epinephrine would not reliably reverse bradykinin-mediated angioedema; repeating epinephrine while the airway progressively narrows delays the definitive intervention required.
Option B: Option B is incorrect because ACEI-induced angioedema and HAE are distinct diagnoses — while both are bradykinin-mediated, the clinical history (ramipril use, no family history of HAE mentioned, first episode in an adult) points to ACEI angioedema as the more likely diagnosis; more importantly, telling the provider to continue ramipril while awaiting C1 inhibitor levels is dangerous — the ACEI must be stopped immediately regardless of whether HAE or ACEI angioedema is the final diagnosis.
Option D: Option D is incorrect because IV epinephrine does not reliably reverse bradykinin-mediated vascular permeability — the mechanism of failure is not pharmacokinetic (subcutaneous vs. IV) but mechanistic (wrong mediator targeted); escalating to IV epinephrine would add arrhythmia and hypertensive crisis risk without addressing the bradykinin-driven swelling.
Option E: Option E is incorrect because H2 receptors do not mediate bradykinin-stimulated vascular permeability — bradykinin acts through B2 receptors coupled to Gq, not through histamine H2 receptors; adding famotidine would provide no benefit in ACEI angioedema, and the expectation of clinical improvement within 15–20 minutes is pharmacologically unsupported.

9. A 26-year-old woman presents to her internist for evaluation of three episodes of facial and abdominal swelling in the past eight months, each lasting 2–4 days and resolving spontaneously. She has no urticaria with the episodes. She takes no ACE inhibitors or ARBs. She reports her mother experienced similar episodes. Allergy skin testing is negative for common allergens. Total IgE is normal. The internist suspects a non-histamine-mediated angioedema syndrome. Which of the following is the most appropriate initial diagnostic workup and explains why these two tests are necessary?

A) Serum tryptase level drawn during an attack, and 24-hour urine histamine measurement between attacks — tryptase is released specifically during IgE-mediated mast cell degranulation and its elevation confirms allergic angioedema; 24-hour urine histamine identifies patients with mastocytosis, in which constitutive mast cell activation produces chronic histamine excess responsible for recurrent angioedema episodes without identifiable allergen triggers
B) Antinuclear antibody (ANA) and complement C3 and C4 levels — recurrent non-urticarial angioedema without a clear allergen trigger in a young woman with a family history suggests lupus-associated complement-mediated angioedema; ANA confirms the autoimmune diagnosis and C3/C4 levels quantify the degree of complement consumption; if confirmed, hydroxychloroquine is the treatment of choice
C) Total complement CH50 and serum IgE panel for food allergens including shellfish, tree nuts, and wheat — the family history suggests a shared dietary trigger that has not been identified; CH50 measures overall complement pathway integrity and would be reduced if complement is being consumed by circulating immune complexes from a food allergen; a supervised food challenge would be the next step if both tests are abnormal
D) Skin prick testing for latex and insect venom allergens, and a trial of high-dose cetirizine 20 mg daily — recurrent non-urticarial angioedema in a young woman most commonly reflects an IgE-mediated reaction to an unidentified occupational or environmental allergen; high-dose antihistamines are therapeutic as well as diagnostic — if symptoms resolve, IgE-mediated allergy is confirmed; if symptoms persist, hereditary angioedema workup is then indicated
E) C1 inhibitor antigen level and C1 inhibitor functional activity — the clinical pattern (recurrent non-urticarial angioedema lasting days, family history, no response to antihistamines, no ACEI exposure) is characteristic of hereditary angioedema; C1 inhibitor antigen identifies type I HAE (reduced antigen) versus type II HAE (normal or elevated antigen with reduced function); both tests together distinguish the subtypes and confirm the diagnosis, because antigen alone will miss type II HAE

ANSWER: E

Rationale:

This question asked you to recognize the clinical pattern of hereditary angioedema and identify the correct diagnostic approach — specifically why both antigen and functional assays are required rather than one alone. The clinical features in this patient are textbook for HAE: recurrent episodic non-urticarial angioedema lasting days (longer than allergic angioedema, which typically resolves within 24–48 hours with appropriate treatment), positive family history consistent with autosomal dominant inheritance, no identifiable allergen trigger, no ACEI exposure, and no response to antihistamines (implied by the previous episodes resolving without treatment rather than with antihistamines). HAE is caused by C1 inhibitor deficiency or dysfunction, leading to unregulated plasma kallikrein activity and bradykinin excess. The correct diagnostic workup is C1 inhibitor antigen level (ELISA) and C1 inhibitor functional activity (chromogenic or functional assay). HAE type I (approximately 85% of cases) shows reduced antigen and reduced function — insufficient C1-INH protein is produced. HAE type II (approximately 15%) shows normal or elevated antigen with markedly reduced functional activity — dysfunctional C1-INH protein is produced in normal or increased quantities but cannot inhibit its target proteases. Measuring antigen alone will miss type II HAE, because antigen levels are normal or high; measuring function alone establishes the diagnosis but does not classify the subtype. Both tests together allow definitive classification.

Option A: Option A is incorrect because tryptase elevation during an attack would confirm IgE-mediated mast cell degranulation, which is not the mechanism in this patient — HAE attacks do not involve mast cell degranulation or tryptase release; 24-hour urine histamine measures histamine metabolites, which are not elevated in HAE; these tests are appropriate for mastocytosis workup, not for recurrent non-urticarial angioedema with a family history.
Option B: Option B is incorrect because lupus-associated angioedema is a very different entity — systemic lupus would typically produce other features (rash, arthritis, serological abnormalities) and the family history does not fit a lupus pattern; ANA and complement studies are not the first-line diagnostic approach for this clinical presentation, which fits HAE much more closely.
Option C: Option C is incorrect because CH50 and food allergen IgE panels are not the appropriate workup — CH50 would be reduced in HAE (because C1-INH regulates the complement system and its deficiency leads to complement consumption), but it is a non-specific screening test that would not distinguish HAE from other complement disorders; food allergen IgE testing is not indicated when there is no clinical suggestion of a food trigger and IgE-mediated allergy has already been excluded.
Option D: Option D is incorrect because high-dose antihistamines are ineffective in HAE — HAE is bradykinin-mediated and antihistamines have no effect on bradykinin-driven angioedema; using antihistamine response as a diagnostic criterion would lead to incorrect classification (HAE episodes resolve spontaneously regardless of treatment, so temporary resolution with antihistamines does not exclude HAE); skin testing for latex and insect venom is not the appropriate next step given the clinical picture.

10. A 34-year-old man with known hereditary angioedema type I (confirmed C1 inhibitor antigen 18% of normal) presents to the emergency department with rapidly progressive laryngeal edema and stridor. He has no epinephrine auto-injector and carries no HAE-specific medication. The triage nurse administers diphenhydramine 50 mg IV and calls for epinephrine. The HAE specialist on call is reached by phone and advises against relying on epinephrine and antihistamines as primary treatment. Which of the following most accurately reflects the specialist's reasoning and identifies the correct pharmacological management?

A) The specialist advises against epinephrine because it paradoxically worsens laryngeal HAE attacks by stimulating beta-2 receptors on laryngeal mast cells, triggering secondary degranulation of tissue mast cells that amplifies bradykinin release; the correct management is methylprednisolone 500 mg IV to suppress the inflammatory cascade, with icatibant reserved for refractory cases
B) The specialist advises that epinephrine and antihistamines are mechanistically incapable of reversing HAE laryngeal edema because the swelling is driven by bradykinin acting at B2 receptors — not by histamine — and the permeability increase is mediated by NO and prostacyclin rather than histamine receptor activation; epinephrine may provide transient partial benefit through vasoconstriction but cannot be relied upon; the correct primary management is C1 inhibitor concentrate, icatibant (a B2 receptor antagonist), or ecallantide (a plasma kallikrein inhibitor), combined with early airway assessment and preparation for definitive airway management if swelling progresses
C) The specialist advises against epinephrine because patients with HAE type I have markedly reduced adrenergic receptor sensitivity due to chronic compensatory downregulation from sustained bradykinin excess; the normal dose of epinephrine (0.3 mg) produces negligible adrenergic receptor activation in these patients and the correct dose is 1.0 mg IM; diphenhydramine is appropriate as a primary agent because HAE laryngeal attacks always have a secondary histamine component that antihistamines address effectively
D) The specialist advises that diphenhydramine is the correct primary agent but the dose is insufficient — HAE type I requires diphenhydramine 200 mg IV because the high tissue bradykinin concentrations in HAE upregulate H1 receptor expression in the laryngeal mucosa by approximately tenfold through a cytokine-mediated mechanism; standard doses saturate fewer than 10% of available H1 receptors at these elevated densities, explaining why standard antihistamine doses appear ineffective
E) The specialist advises against epinephrine in HAE because propranolol — a beta-blocker that is a common trigger for HAE attacks — is contraindicated in HAE patients and may have been given to this patient previously; the concern is that residual propranolol activity is blocking epinephrine's beta-2 effects; the correct management is glucagon to bypass beta-receptor blockade, followed by icatibant once beta-blocker reversal is confirmed

ANSWER: B

Rationale:

This question asked you to apply the mechanistic distinction between histamine-mediated and bradykinin-mediated angioedema to a life-threatening laryngeal HAE emergency, and to identify the pharmacologically correct treatment. HAE type I results from C1 inhibitor deficiency — unrestrained plasma kallikrein generates bradykinin from HMWK, and bradykinin accumulates at laryngeal submucosal vasculature. Bradykinin activates B2 receptors coupled to Gq, generating intracellular calcium that activates eNOS (producing NO) and phospholipase A2 (producing arachidonate for prostacyclin synthesis via COX-1). These mediators increase vascular permeability through endothelial gap formation — a process entirely independent of histamine receptor activation. Because histamine is not the mediator, diphenhydramine blocking H1 receptors provides no meaningful benefit. Epinephrine may provide some transient partial benefit through alpha-1 vasoconstriction counteracting vasodilation, but it cannot reverse NO- and prostacyclin-mediated endothelial permeability with the speed or reliability that characterizes its reversal of histamine-mediated anaphylaxis. Relying on epinephrine and antihistamines while laryngeal swelling progresses risks fatal airway obstruction. The correct pharmacological treatments target the kallikrein-kinin cascade directly: C1 inhibitor concentrate (plasma-derived or recombinant) restores the missing serine protease inhibitor; icatibant (a B2 receptor antagonist) blocks the receptor through which bradykinin causes permeability; ecallantide (a plasma kallikrein inhibitor) prevents bradykinin generation at the enzyme level. All require early airway assessment — if laryngeal HAE progresses to imminent obstruction despite treatment, early intubation or surgical airway is required because HAE swelling responds much more slowly than histamine-mediated anaphylaxis to any treatment.

Option A: Option A is incorrect because epinephrine does not paradoxically stimulate mast cell beta-2 receptors to amplify bradykinin release — this mechanism is pharmacologically fabricated; mast cell beta-2 receptor activation by epinephrine actually inhibits degranulation through cAMP elevation; and methylprednisolone is not an effective primary treatment for HAE attacks — corticosteroids suppress cytokine-driven inflammation but have no effect on the kallikrein-kinin protease cascade generating bradykinin.
Option C: Option C is incorrect because chronic bradykinin excess in HAE does not cause adrenergic receptor downregulation — adrenergic receptor sensitivity is not reduced in HAE patients, and the dose of epinephrine is not the primary issue; diphenhydramine is not an appropriate primary agent for HAE laryngeal attacks because histamine is not the mediator.
Option D: Option D is incorrect because bradykinin does not upregulate H1 receptor expression in the laryngeal mucosa through a cytokine mechanism, and HAE attacks do not have a secondary histamine component that antihistamines address; increasing diphenhydramine dose cannot overcome a mechanistic mismatch — no dose of an H1 blocker can reverse bradykinin-mediated permeability.
Option E: Option E is incorrect because the question gives no clinical indication that this patient has received propranolol; HAE triggers include stress, trauma, and estrogen-containing medications, not propranolol specifically; glucagon is indicated for beta-blocker-refractory epinephrine failure in anaphylaxis, not as primary therapy for HAE laryngeal attacks, which require bradykinin-targeted treatment.

11. A 70-year-old man with heart failure with reduced ejection fraction was on enalapril 10 mg twice daily for several years. His cardiologist decides to transition him to sacubitril-valsartan for improved outcomes. The last enalapril dose was taken at 8 pm; sacubitril-valsartan is started at 4 pm the following day — 20 hours later. Three days after initiating the new regimen, the patient develops tongue swelling and lip edema without urticaria. He calls his cardiologist's office. The covering physician reviews the medication transition and identifies the pharmacological basis for the complication. Which of the following correctly explains what occurred and how it should have been prevented?

A) The complication occurred because valsartan and enalapril share a common binding site at the angiotensin II type 1 receptor; when both drugs are present simultaneously — even at low residual enalapril concentrations — they produce synergistic AT1 receptor blockade that activates a compensatory bradykinin synthesis pathway through renin-angiotensin system remodeling; a 36-hour washout would not have prevented this because the synergistic interaction requires only nanomolar concentrations of each drug
B) The complication occurred because sacubitril-valsartan causes angioedema as a class effect of ARBs independent of ACE inhibitor co-exposure; valsartan's complete AT1 receptor blockade prevents angiotensin II from suppressing bradykinin release from endothelial cells through its normal AT1 receptor-mediated inhibitory signaling; the correct prevention would have been choosing a different antihypertensive class rather than any ARB-containing regimen
C) The complication occurred because sacubitril inhibits renal OAT3-mediated enalaprilat excretion, extending enalaprilat's effective half-life and maintaining residual ACE inhibition well beyond 20 hours; a 36-hour washout of enalapril was specified in guidelines specifically because sacubitril's OAT3 inhibitory effect doubles enalaprilat's half-life; the pharmacokinetic interaction between sacubitril and enalaprilat clearance is the recognized mechanism for this adverse event
D) The complication occurred because sacubitril inhibits neprilysin, one of the two major bradykinin-degrading enzymes, while residual enalaprilat — still present at 20 hours given enalapril's active metabolite half-life — continued to inhibit ACE (kininase II), the other major bradykinin-degrading enzyme; with both degradation pathways simultaneously blocked, bradykinin accumulated to levels sufficient to cause angioedema; the 36-hour washout requirement exists precisely to allow enalaprilat concentrations to fall below the threshold for clinically significant ACE inhibition before neprilysin inhibition is introduced
E) The complication occurred because enalapril and sacubitril-valsartan are both metabolized by CYP3A4, and their co-administration during the transition period produced competitive inhibition of CYP3A4-mediated clearance; the resulting elevation in sacubitril plasma concentrations increased neprilysin inhibition beyond the intended therapeutic level, causing bradykinin accumulation; a 36-hour washout would not have been necessary if a lower starting dose of sacubitril-valsartan had been used

ANSWER: D

Rationale:

This question asked you to apply the dual bradykinin degradation pathway — ACE (kininase II) and neprilysin — to a real clinical transition error and explain why the 36-hour washout rule is pharmacologically essential. Bradykinin is degraded in plasma and vascular tissue primarily by two enzymes: ACE (kininase II), which cleaves the C-terminal dipeptide Phe-Arg; and neprilysin (neutral endopeptidase), which cleaves internal bonds. Under physiological conditions, both enzymes together maintain bradykinin below the threshold for clinically significant permeability increase. Sacubitril-valsartan introduces LBQ657 (sacubitril's active metabolite) as a potent neprilysin inhibitor, eliminating one of the two degradation pathways. At the same time, enalaprilat — the active metabolite of enalapril — has a half-life of approximately 11 hours in normal renal function, meaning that 20 hours after the last enalapril dose, a pharmacologically significant concentration of enalaprilat persists. With both ACE and neprilysin inhibited simultaneously, bradykinin accumulates profoundly, and the tongue and lip swelling observed is the direct consequence. The 36-hour minimum washout requirement exists to allow enalaprilat concentrations to decline to levels below the threshold for meaningful ACE inhibition before neprilysin inhibition is introduced. In patients with renal impairment (where enalaprilat clearance is reduced), the required washout may need to be even longer. This complication has a documented fatality risk from laryngeal involvement and represents one of the few absolute contraindications in cardiovascular pharmacotherapy — sacubitril-valsartan within 36 hours of any ACE inhibitor.

Option A: Option A is incorrect because enalapril and valsartan do not share a binding site — enalapril inhibits ACE (a dipeptidase enzyme), while valsartan blocks the AT1 receptor (a GPCR); they act at pharmacologically distinct targets; the described synergistic AT1 blockade activating a compensatory bradykinin synthesis pathway is mechanistically fabricated.
Option B: Option B is incorrect because ARBs alone carry a much lower angioedema risk (approximately 10% of ACEI risk) because they do not inhibit ACE and therefore do not impair bradykinin degradation; the complication in this case is specifically caused by the combination of residual ACE inhibition and new neprilysin inhibition — not by valsartan's AT1 blockade alone.
Option C: Option C is incorrect because the established mechanism of this adverse event is pharmacodynamic dual bradykinin pathway blockade, not pharmacokinetic extension of enalaprilat half-life through OAT3 inhibition by sacubitril; while drug transporter interactions are recognized, OAT3 inhibition by sacubitril is not the guideline-stated reason for the 36-hour washout; attributing the interaction to transporter pharmacokinetics rather than dual enzyme inhibition misidentifies the mechanism.
Option E: Option E is incorrect because enalapril is not primarily metabolized by CYP3A4 — it is hydrolyzed to enalaprilat by esterases and renally eliminated; sacubitril is similarly hydrolyzed by esterases, not CYP3A4; competitive CYP3A4 inhibition is not the mechanism of interaction between these two drugs, and the proposed dose-reduction solution would not address the dual bradykinin degradation pathway problem.